The New Biomarker for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Based on Public Database Mining.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

Adenocarcinoma*/diagnosis ; Adenocarcinoma*/genetics ; Adenocarcinoma*/metabolism ; Biomarkers, Tumor*/genetics ; Biomarkers, Tumor*/metabolism ; Carcinoma, Squamous Cell*/diagnosis ; Carcinoma, Squamous Cell*/genetics ; Carcinoma, Squamous Cell*/metabolism ; Databases, Nucleic Acid* ; Neoplasm Proteins*/genetics ; Neoplasm Proteins*/metabolism ; RNA, Neoplasm*/genetics ; RNA, Neoplasm*/metabolism ; Uterine Cervical Neoplasms*/diagnosis ; Uterine Cervical Neoplasms*/genetics ; Uterine Cervical Neoplasms*/metabolism; Data Mining ; Female ; Humans

To reconstruct the ceRNA biological network of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and to select an appropriate mRNA as a biomarker that could be used for CESC early diagnosis and prognosis evaluation. We downloaded CESC data from the TCGA public database, and statistical analysis was conducted with the R software to find out differential expressed genes encoding for lncRNAs, miRNAs, and mRNAs. The differentially expressed mRNAs (DEmRNAs) screened in the ceRNA network were analyzed for survival to find the mRNAs with significantly linked to the survival prognosis. These mRNAs were searched in the Pathological Atlas to identify the final appropriate mRNAs. Differential expression analysis revealed 773 lncRNAs, 94 miRNAs, and 2466 mRNAs. Survival analysis of DEmRNAs in the ceRNA network indicated that ADGRF4, ANXA8L1, HCAR3, IRF6, and PDE2A ( P < 0.05) were negatively correlated with survival time. Verification of these six DEmRNAs in the Pathology Atlas indicated that PDE2A was a possible biomarker for CESC patients. PDE2A might be a biomarker for early diagnosis and prognosis evaluation of CESC patients, but due to the lack of available data, further studies may be needed for confirmation.
Competing Interests: The authors declare that there are no conflicts of interest.
(Copyright © 2020 Hao Ding et al.)

Novartis Found Symp. 2002;247:91-101; discussion 101-3, 119-28, 244-52. (PMID: 12539951)
J Med Chem. 2017 Mar 9;60(5):2037-2051. (PMID: 28165743)
Cell Mol Life Sci. 2018 Feb;75(3):467-484. (PMID: 28840253)
Nat Med. 2015 Nov;21(11):1253-61. (PMID: 26540387)
Nature. 2014 Feb 20;506(7488):371-5. (PMID: 24390348)
Vascul Pharmacol. 2019 Mar;114:145-156. (PMID: 29425892)
Cancer Lett. 2017 Sep 10;403:305-317. (PMID: 28687357)
Bioorg Med Chem Lett. 2013 Dec 15;23(24):6522-7. (PMID: 24189054)
Nat Genet. 2018 Jun;50(6):783-789. (PMID: 29785014)
Bioinformatics. 2008 Jan 15;24(2):282-4. (PMID: 18006545)
Cancer Genet. 2016 Oct;209(10):463-473. (PMID: 27810075)
Oncol Rep. 2013 Apr;29(4):1275-84. (PMID: 23381931)
Nucleic Acids Res. 2003 Jan 1;31(1):258-61. (PMID: 12519996)
J Pharmacol Exp Ther. 2018 Apr;365(1):179-188. (PMID: 29440309)
Cell Prolif. 2019 Jul;52(4):e12628. (PMID: 31038266)
J Cell Physiol. 2018 Sep;233(9):6822-6831. (PMID: 29319172)
Mov Disord. 2018 Mar;33(3):482-488. (PMID: 29392776)
J Cell Physiol. 2019 Aug;234(10):18837-18848. (PMID: 30916406)
J Pathol. 2008 Dec;216(4):387-93. (PMID: 18853439)
Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991)
Nucleic Acids Res. 2012 Jan;40(Database issue):D565-70. (PMID: 22123736)
FEBS J. 2014 Aug;281(16):3609-24. (PMID: 24942287)
J Cell Physiol. 2020 Mar;235(3):2464-2477. (PMID: 31502679)
Nature. 2015 Jul 23;523(7561):459-462. (PMID: 26131930)
Curr Opin Oncol. 2018 Sep;30(5):323-329. (PMID: 29994902)
Int J Technol Assess Health Care. 2015 Jan;31(3):171-80. (PMID: 26179276)
Int J Cancer. 2018 Aug 15;143(4):944-957. (PMID: 29516499)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Mol Carcinog. 2019 Apr;58(4):554-564. (PMID: 30520151)
Cell. 2018 Apr 5;173(2):283-285. (PMID: 29625045)
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):319-324. (PMID: 29479954)
J Nucl Med. 2016 Sep;57(9):1388-95. (PMID: 27103022)
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. (PMID: 30659131)
Cell. 2011 Aug 5;146(3):353-8. (PMID: 21802130)
Oncol Lett. 2018 Jun;15(6):8965-8972. (PMID: 29805632)
Bioinformatics. 2016 Jun 1;32(11):1716-23. (PMID: 26826716)
Cancer Med. 2015 Oct;4(10):1573-82. (PMID: 26256448)
Oncotarget. 2017 Dec 13;9(4):4798-4813. (PMID: 29435142)
Arch Pathol Lab Med. 2018 Jun;142(6):688-692. (PMID: 29848034)
Asian Pac J Cancer Prev. 2013;14(9):5101-5. (PMID: 24175783)
Cancer. 2017 Jul 1;123(13):2404-2412. (PMID: 28464289)
Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R17-29. (PMID: 16651366)

0 (Biomarkers, Tumor)
0 (Neoplasm Proteins)
0 (RNA, Neoplasm)

Date Created: 20200501 Date Completed: 20210210 Latest Revision: 20210210

20221213

PMC7174939

10.1155/2020/5478574

32351997